Runway Math for Biotech and Digital Health Founders: Making Every Dollar Reach the Next Milestone

Picture a founder at a whiteboard in month fourteen of an eighteen-month plan. The lead compound looks good. The animal study that will prove it is booked with a contract research organization, but the start date just slipped by a quarter. Nothing is broken in the science. The problem is that the bank balance was built for a calendar, and biology does not follow calendars.

The direct answer: runway for a biotech or digital health company should be measured in milestones, not months. Budget backward from the next value inflection point (the data readout, regulatory step or commercial proof that changes your valuation), add a realistic buffer for delays, and layer in non-dilutive funding so equity is spent only on work that moves that milestone forward. If the cash cannot reach the milestone with room to spare, change the plan now, while you still have options.

Why Biotech and Digital Health Runway Calculations Go Wrong

The classic runway formula is simple: cash on hand divided by monthly net burn. Net burn is the amount of cash a company loses each month after any revenue comes in. The formula is fine for a stable software company. For a lab-based or clinical-stage business, it hides most of the risk.

Spending in life sciences is lumpy. One study or manufacturing run can consume a large share of the budget in a month or two, and an average burn number smooths those spikes away.

Digital health companies face a different version of the same trap. A health SaaS product may have revenue, but sales cycles with hospitals and health systems are long, pilots often come before paid contracts, and security reviews can add months. Founders who forecast software-style growth on a healthcare buying cycle tend to raise their next round in a hurry.

The Three Hidden Drains on Life Sciences Cash

• Timeline slippage. A delayed study keeps the whole team on payroll for extra months with no new data to show investors.
• Vendor minimums and prepayments. Contract research and manufacturing partners often require deposits well before work begins, which pulls cash forward.
• Scope creep in the science. An extra cohort or an added endpoint can be the right scientific call, but it needs a funding decision, not a quiet budget change.

What Is Milestone-Based Budgeting for a Biotech Company?

Milestone-based budgeting is a planning method that ties every major spending line to a specific scientific, regulatory or commercial outcome. Instead of asking how much the company will spend next year, the founder asks what it costs to reach the next result an investor or partner will pay for.

Every request for a new hire or a new assay then faces one question: does this get us to the milestone faster, more cheaply or with less risk? If not, it waits.

Building the Milestone Map

Start by naming the next one or two value inflection points. For a preclinical therapeutics company, that might be a candidate nomination and then an IND-enabling package. For a diagnostics startup, it could be analytical validation followed by a regulatory filing. For a health SaaS company, it may be the first paid enterprise contract and then proof of renewal.

Then list every activity required before each milestone, with its cost, vendor and likely duration. Mark the activities on the critical path, where a delay pushes the whole timeline, and track them closely.

Separating Must-Have Spend From Nice-to-Have Spend

Every budget line should carry one of three tags: required for the milestone, helpful for the milestone, or aimed at the milestone after that. The third category is where founders often overspend early. Building a commercial team before the clinical data exists is a common example.

How Much Runway Should a Biotech or Health Tech Founder Hold?

Many investors expect a company to raise enough to cover the next milestone plus a cushion, often cited as roughly 18 to 24 months of runway after a round closes. The cushion matters because fundraising itself takes time. Founders commonly start the next raise six to nine months before cash would run out.

The right number depends on the business model, as the comparison below shows.

Company type	Main cash drivers	Typical runway risk	Planning focus
Therapeutics biotech	Studies, CRO and CMO contracts, regulatory work	Study delays and lumpy vendor payments	Milestone budgets with delay scenarios
Digital health platform	Engineering, clinical staff, compliance	Long pilots before paid contracts	Conversion from pilot to contract
Health SaaS	Product, sales, security and integrations	Slow enterprise sales cycles	Sales cycle length and burn multiple

A capable Fractional CFO for biotech companies will usually model at least three cases: the plan, a delayed case where the critical path slips by a quarter or two, and a severe case where a key result needs to be repeated. If the company cannot survive the delayed case, the plan needs more cash, less spending or a different milestone.

Non-Dilutive Funding: Grants, Contracts and Partnerships

Non-dilutive funding is capital that does not require giving up ownership in the company. In life sciences and health technology, it can come from government grants, research contracts, foundation awards, strategic partnerships and certain tax credits. Used well, it lets equity dollars go further.

Grants: Valuable, Slow and Restricted

Federal programs such as SBIR and STTR fund early research at many U.S. life sciences and health tech companies. Agencies like the NIH also run specific programs for small businesses. The catch is timing. Review cycles can take many months, so grant money rarely solves a near-term cash problem.

Grant funds also come with rules. Spending usually must match the approved budget, costs must be tracked by project, and indirect cost rates need support. Founders who win a grant without the accounting systems to manage it can create audit problems later.

Partnerships and Tax Credits

A licensing or co-development deal with a larger company can bring upfront fees and milestone payments. These deals trade some future value for cash today, so they need careful modeling. The question is whether the partnership funds work you would have done anyway, or pulls the team away from the core program.

The federal R&D tax credit is another lever that early companies often overlook. Qualifying small businesses may be able to apply part of the credit against payroll taxes, which can matter before the company has income tax to offset. The rules are technical, so founders should work with a qualified tax advisor before counting on it.

Runway Extension Levers That Protect the Science

When the math does not reach the milestone, founders have more choices than a bridge round at a painful price. The best levers stretch cash without slowing the critical path.

1. Renegotiate vendor payment schedules. Ask CROs and manufacturers to tie payments to deliverables instead of large upfront deposits.
2. Resequence non-critical work. Push activities tagged for the following milestone into the next funding period.
3. Convert fixed costs to variable ones. Use shared lab space, contract specialists or part-time finance leadership instead of early full-time hires.
4. Tighten the milestone definition. Agree with investors on the smallest data package that proves the point, and avoid gold-plating.
5. Stack non-dilutive sources. Pair a grant with a tax credit or a small partnership so no single source carries the plan.

Digital health companies have an extra lever: revenue quality. An Outsourced CFO for healthcare startups can help a founder structure pilots with clear conversion terms, paid phases and defined success metrics. A free pilot that never converts is one of the most expensive things a young health company can run.

For health SaaS companies, discipline around customer acquisition matters just as much. Working with an Outsourced CFO for SaaS startups often brings in metrics like the burn multiple, which compares net burn to new recurring revenue. A rising burn multiple is an early sign that growth is costing more than the runway can afford.

Building a Runway Model Investors Will Believe

Investors in biotech and digital health have seen many optimistic plans. A credible model earns trust by being honest about timing, vendor terms and what happens if things slip.

Firms such as K-38 Consulting, a Raleigh, North Carolina firm that provides fractional and outsourced CFO services to biotech, healthcare and SaaS companies nationwide, typically build these models so founders can update them monthly rather than once per fundraise. A model that lives with the business is far more useful than a slide built the week before a pitch.

What the Model Should Include

• A monthly cash forecast for at least the next 18 months
• Committed versus uncommitted spend for each major vendor
• Expected timing and restrictions for every grant or partnership dollar
• A clear trigger date for starting the next raise

The trigger date is the piece founders most often skip. It marks when, under the delayed case, fundraising must start to close before cash hits a safe floor. Put it on the board calendar.

Reaching the Milestone With Cash to Spare

Runway is not a number you check once a quarter. For biotech, health tech and health SaaS founders, it is a planning discipline that links each dollar to the result that will justify the next one. Budget backward from the milestone, plan for delays, and treat non-dilutive funding as a real part of the capital stack.

Founders who reach their data readout or first enterprise renewal with months of cash in the bank negotiate from strength. Those who arrive with weeks left often accept terms they regret.

Runway Questions From the Lab and the Clinic

What is a value inflection point in biotech?

A value inflection point is a result that meaningfully changes how investors or partners value a company. Examples include positive preclinical data, regulatory clearance to begin human trials, clinical readouts or a first major commercial contract. Biotech founders plan budgets around reaching these points because each one usually supports a higher valuation, which makes the next round of funding less dilutive for existing shareholders.

How do you calculate runway for a biotech startup?

Start with cash on hand and subtract committed spending month by month, using the actual timing of study payments and vendor deposits rather than an average burn rate. Then compare the date cash reaches a safe minimum against the expected date of the next milestone. Running the same model with a delayed timeline shows whether the company can absorb common setbacks.

Can grant funding replace venture capital for a biotech company?

Grants rarely replace venture capital entirely, but they can reduce how much equity a company needs to sell. Programs like SBIR and STTR fund specific research projects, often in stages. Because review cycles are slow and funds carry spending restrictions, most founders use grants to fund defined work packages while equity covers broader operating costs and later-stage development.

When should a digital health startup start its next fundraise?

Many digital health founders begin raising six to nine months before cash would fall below a safe minimum, because rounds often take longer than expected. The safest approach is to set a trigger date based on a delayed scenario, not the base plan. That date should be tracked by the board so fundraising starts on time rather than in a rush.

What is the burn multiple and why does it matter for health SaaS?

The burn multiple is net cash burn divided by net new annual recurring revenue over the same period. It shows how much cash a company spends to add each dollar of recurring revenue. For health SaaS companies with long enterprise sales cycles, a rising burn multiple signals that growth is becoming expensive and that runway may shrink faster than planned.